Roche's New EPO: "White Knight" or Wolf in Sheep's Clothing?
This article was originally published in RPM Report
Executive Summary
After years of dueling with nemesis Johnson & Johnson, Amgen faces a new threat to its EPO business with the pending approval of Roche's Mircera. Roche says they are coming to the rescue of doctors who are ready for another option. Amgen claims a Swiss company is out to gouge Medicare and US taxpayers.